Citadel Advisors LLC Buys New Shares in Palvella Therapeutics (NASDAQ:PVLA)

Citadel Advisors LLC purchased a new position in Palvella Therapeutics (NASDAQ:PVLA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,408 shares of the company's stock, valued at approximately $125,000. Citadel Advisors LLC owned approximately 0.09% of Palvella Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Geode Capital Management LLC acquired a new stake in shares of Palvella Therapeutics in the 4th quarter worth $171,000. Renaissance Technologies LLC acquired a new stake in Palvella Therapeutics during the fourth quarter worth about $256,000. BML Capital Management LLC acquired a new stake in Palvella Therapeutics during the fourth quarter worth about $506,000. ADAR1 Capital Management LLC purchased a new position in Palvella Therapeutics during the fourth quarter worth about $1,736,000. Finally, Nantahala Capital Management LLC acquired a new position in Palvella Therapeutics in the 4th quarter valued at about $3,001,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PVLA. Chardan Capital began coverage on shares of Palvella Therapeutics in a report on Wednesday, April 9th. They set a "buy" rating and a $50.00 price target for the company. Jones Trading initiated coverage on Palvella Therapeutics in a research note on Tuesday, March 25th. They set a "buy" rating and a $45.00 target price for the company. Canaccord Genuity Group reduced their target price on Palvella Therapeutics from $53.00 to $52.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Scotiabank assumed coverage on Palvella Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price target for the company. Finally, HC Wainwright reissued a "buy" rating and set a $38.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, April 30th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $46.29.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, Director George M. Jenkins acquired 2,500 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average price of $20.13 per share, for a total transaction of $50,325.00. Following the completion of the acquisition, the director now owns 183,171 shares of the company's stock, valued at approximately $3,687,232.23. This trade represents a 1.38% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 20.50% of the company's stock.

Palvella Therapeutics Price Performance

NASDAQ:PVLA traded up $1.10 during trading hours on Thursday, reaching $26.42. 66,022 shares of the stock were exchanged, compared to its average volume of 69,380. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $29.27. The stock has a 50-day simple moving average of $23.54. The stock has a market cap of $292.10 million, a P/E ratio of -2.18 and a beta of -0.10.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.40) by $2.66. As a group, analysts forecast that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.